Volume 76, Issue 3, Pages 368-380 (September 2019) Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019  Marc-Oliver Grimm, Axel Bex, Maria De Santis, Börje Ljungberg, James W.F. Catto, Morgan Rouprêt, Syed A. Hussain, Joaquim Bellmunt, Tom Powles, Manfred Wirth, Hendrik Van Poppel  European Urology  Volume 76, Issue 3, Pages 368-380 (September 2019) DOI: 10.1016/j.eururo.2019.05.041 Copyright © 2019 Terms and Conditions

Fig. 1 Recommendations dependent on irAE type/severity for treatment modifications of ICI therapy. Various colors indicate that treatment may be continued (green), should be interrupted (yellow), or should be discontinued permanently (red; assessment based on drug manufacturers’ current prescribing information text according to Table 2). ADR=adverse drug reaction; AE=adverse event; ALT=alanine transaminase; AST=aspartate transaminase Ate=atezolizumab; BILI=bilirubin; CREA=creatinine; CTCAE=Common Terminology Criteria for Adverse Events; ICI=immune checkpoint inhibitor; irAE=immune-related adverse event; Niv=nivolumab; Pem=pembrolizumab; SmPC=summaries of product characteristics; syndr.=syndrome; TSH=thyroid-stimulating hormone. European Urology 2019 76, 368-380DOI: (10.1016/j.eururo.2019.05.041) Copyright © 2019 Terms and Conditions